Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The evolving place of incretin-based therapies in type 2 diabetes Gallwitz BPediatr Nephrol 2010[Jul]; 25 (7): 1207-17Treatment options for type 2 diabetes based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were first introduced in 2005. These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4. In adult medicine, both treatment options are attractive and more commonly used because of their action and safety profile. The incretin-based therapies stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner and carry no intrinsic risk of hypoglycaemia. GLP-1 receptor agonists allow weight loss, whereas DPP-4 inhibitors are weight neutral. This review gives an overview of the mechanism of action and the substances and clinical data available.|*Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use[MESH]|Adolescent[MESH]|Adult[MESH]|Animals[MESH]|Child[MESH]|Diabetes Mellitus, Type 2/*drug therapy[MESH]|Dipeptidyl Peptidase 4[MESH]|Disease Models, Animal[MESH]|Glucagon-Like Peptide 1/*therapeutic use[MESH]|Glucagon/metabolism/physiology[MESH]|Humans[MESH]|Hypoglycemic Agents/*therapeutic use[MESH]|Insulin Secretion[MESH]|Insulin/metabolism/physiology[MESH] |
